{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-142000","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.368389+00:00","generated_at":"2026-06-15T04:56:51.204718+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IO Biotech reports Q1 net loss of $17.0M; Phase 3 melanoma trial on track for mid-2023 enrollment milestone","bullets":["Net loss $17.0M for Q1 2023, nearly flat vs $17.2M in Q1 2022.","Cash and equivalents $128.5M as of March 31, 2023; expected to fund operations through Q3 2024.","Phase 3 pivotal trial (IOB-013) in advanced melanoma: expects 225 patients randomized by mid-2023, full enrollment by end of 2023.","Phase 2 basket trial (IOB-022) in lung cancer: 4 partial responses, 4 stable disease among 9 evaluable patients; safety consistent.","FDA cleared IND for IO102-IO103 in neo-adjuvant/adjuvant solid tumors; Phase 2 trial to start H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-142000","json":"https://secwatch.observer/filing/0001193125-23-142000.json","markdown":"https://secwatch.observer/filing/0001193125-23-142000.md","text":"https://secwatch.observer/filing/0001193125-23-142000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523142000/0001193125-23-142000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523142000/d471457d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:56:51.204718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9b60871cfb9b4e30123f1c536fe3cb2c867e4ee","claim":"IO Biotech, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023 was $17.0 million.","evidence_excerpt":"Net loss for the three months ended March 31, 2023 was $17.0 million, compared to $17.2 million for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523142000/0001193125-23-142000-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2023 was $17.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}